Suggestion of a dual‐functional agent for future trials in nonalcoholic fatty liver disease
Liang Shen – 29 October 2010
Activation of LKB1‐Akt pathway independent of phosphoinositide 3‐kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis
Nuria Martínez‐López, Marta Varela‐Rey, David Fernández‐Ramos, Ashwin Woodhoo, Mercedes Vázquez‐Chantada, Nieves Embade, Luis Espinosa‐Hevia, Francisco Javier Bustamante, Luis A. Parada, Manuel S. Rodriguez, Shelly C. Lu, José M. Mato, Maria L. Martínez‐Chantar – 29 October 2010 – LKB1, originally considered a tumor suppressor, plays an important role in hepatocyte proliferation and liver regeneration.
A novel GSK‐3 beta–C/EBP alpha–miR‐122–insulin‐like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma
Chunxian Zeng, Ruizhi Wang, Daochuan Li, Xue‐Jia Lin, Qing‐Kun Wei, Yunfei Yuan, Qing Wang, Wen Chen, Shi‐Mei Zhuang – 29 October 2010 – miR‐122 is a highly abundant, hepatocyte‐specific microRNA. The biomedical significance and regulatory mechanisms of miR‐122 remain obscure. We explored the role of miR‐122 in tumorigenesis in the context of gene regulatory network. The miR‐122 promoter and its transactivator were identified by way of luciferase reporter system, electrophoretic mobility shift, and chromatin immunoprecipitation assays.
Adenosine triphosphate release and purinergic (P2) receptor–mediated secretion in small and large mouse cholangiocytes
Kangmee Woo, Meghana Sathe, Charles Kresge, Victoria Esser, Yoshiyuki Ueno, Julie Venter, Shannon S. Glaser, Gianfranco Alpini, Andrew P. Feranchak – 29 October 2010 – Adenosine triphosphate (ATP) is released from cholangiocytes into bile and is a potent secretogogue by increasing intracellular Ca2+ and stimulating fluid and electrolyte secretion via binding purinergic (P2) receptors on the apical membrane.
Randomized controlled trial of pegylated interferon‐alfa 2a and ribavirin in treatment‐naive chronic hepatitis C genotype 6
Khoa D. Lam, Huy N. Trinh, Son T. Do, Thuan T. Nguyen, Ruel T. Garcia, Tuan Nguyen, Quang Q. Phan, Huy A. Nguyen, Khanh K. Nguyen, Long H. Nguyen, Mindie H. Nguyen – 29 October 2010 – Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known.
Is radioembolization ready for the barcelona clinic liver cancer staging system?
Laura Kulik – 29 October 2010
Hypouricemic therapy: A novel potential therapeutic option for nonalcoholic fatty liver disease
Cheng‐Fu Xu, Chao‐Hui Yu, Lei Xu, Xiao‐Ying Sa, You‐Ming Li – 29 October 2010
Pegylated interferon and ribavirin in real life: Efficacy versus effectiveness
Ângelo Zambam de Mattos, Paulo Roberto Lerias de Almeida, Cristiane Valle Tovo, Angelo Alves de Mattos – 29 October 2010
Overlapping high‐resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma
Chian‐Feng Chen, En‐Chi Hsu, Kuen‐Tyng Lin, Pang‐Hsien Tu, Hung‐Wei Chang, Chin‐Hui Lin, Yann‐Jang Chen, De‐Leung Gu, Chi‐Hung Lin, Jer‐Yuarn Wu, Yuan‐Tsong Chen, Ming‐Ta Hsu, Yuh‐Shan Jou – 29 October 2010 – Recurrent cancer genome aberrations are indicators of residing crucial cancer genes. Although recent advances in genomic technologies have led to a global view of cancer genome aberrations, the identification of target genes and biomarkers from the aberrant loci remains difficult.